[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-mellitus-dm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-mellitus-dm":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100628745","evaluating-the-efficacy-of-pulsating-electromagnetic-field-therapy-by-crad-ulcer-x-01-for-diabetic-foot-ulcers-100628745",false,"NCT07465640","Evaluating the Efficacy of Pulsating Electromagnetic Field Therapy by CRAD ULCER X-01 for Diabetic Foot Ulcers","Evaluating the Efficacy of Pulsating Electromagnetic Field (PEMF) Therapy for Diabetic Foot Ulcers Using the CRAD ULCER X-01 Device: A Randomised Parallel-Group Pilot Study","Inclusion Criteria:\n\n* Provision of written consent by subjects.\n* Subject of either sex.\n* At least 18 years of age.\n* Known diabetes mellitus.\n* Diagnosed with chronic DFU Grade I-III and Stage A according to the University of Texas Classification as recommended in the Malaysian Clinical Practice Guidelines for the Management of Diabetic Foot (2nd Edition).\n\nExclusion Criteria:\n\n* Inability or unwillingness to provide written consent.\n* Inability or unwillingness to comply with the requirements of the protocol as determined by the investigator.\n* Other medical conditions which, in the investigator's judgement, may be associated with increased risk to the subject or may interfere with study assessments or outcomes.\n* Participation in another clinical trial and\u002For recipient of investigational therapy within 4 weeks prior to screening visit.\n* Patients who have metal implants in any part of the body.\n* Patients with a pacemaker.\n* History of malignancies.\n* Presence of chronic kidney disease co-morbidity.\n* Presence of severe peripheral artery disease, assessed when the ankle-brachial index (ABI) is \\\u003C0.40.","ALL","18 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"NA","Background: Diabetic foot ulcer (DFU) is a frequent complication of chronic, uncontrolled diabetes mellitus (DM). Treatment with antibiotics, daily dressing, wound debridement, and wound off-loading is often prescribed. However, many DFU patients still progress into severe outcomes, including non-healing of wounds, infections, necrosis, and osteomyelitis. Prior research has shown that the application of pulsating electromagnetic field (PEMF) could accelerate wound healing, including in those afflicted with DFUs. Therefore, this study aimed to evaluate the efficacy of a locally developed CRAD ULCER X-01 device that uses the principles of PEMF in promoting DFU healing. Methods: A total of 32 patients with chronic, non-healing DFUs will be recruited from the Orthopaedic Clinic of Hospital Angkatan Tentera Tuanku Mizan and divided into control (C) (n=8) and treatment (T) (n=24) groups. All patients will receive a standard daily dressing. The PEMF will be supplemented for 1 hour\u002Fday, 2 hours\u002Fday, and 3 hours\u002Fday for T1, T2, and T3 subgroups, respectively (n=8 per group); whereas the C group will be controlled for placebo effect (device in-place but switched off). The therapy duration will be until the wound is closed or for a maximum period of three months. All patients will undergo wound assessment, wound edge tissue histology by haematoxylin and eosin (H\\&E) staining, and immunohistology (for vascular endothelial growth factor \\[VEGF\\] and fibroblast growth factor 2 \\[FGF-2\\] expression), as well as serum superoxide dismutase (SOD) and C-reactive protein (CRP) at preand post-treatment, along with glycated haemoglobin (HbA1c) measurement only at post-treatment to control for confounder (i.e., glucose control for the past three months). This study hypothesizes that PEMF therapy by CRAD ULCER X-01 device will accelerate DFU healing and improve tissue integrity, with minimal systemic effects assessed via oxidative stress and inflammatory markers. Conclusion: The results from this study will validate PEMF's effectiveness in promoting DFU healing and establish the potential use of locally developed CRAD ULCER X-01 devices as supplementary therapy to standard DFU care.",[26,27],"Diabetic Foot Ulcer","Diabetes Mellitus (DM)",[29,30,31,32,33,34],"pulsating electromagnetic field","wound healing","oxidative stress","inflammation","diabetic foot ulcer","diabetes mellitus","NOT_YET_RECRUITING","2026-03-11",{"date":38,"type":39},"2026-03-13","ACTUAL",{"date":38,"type":20},{"date":42,"type":20},"2027-04-01",{"name":44,"class":45},"National Defence University of Malaysia","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100626214","this-study-is-conducted-to-evaluate-the-18-month-clinical-performance-of-complete-bioactive-restorative-system-for-occlusal-restorations-between-diabetic-and-non-diabetic-patients-100626214","NCT07432724","This Study is Conducted to Evaluate the 18-month Clinical Performance of Complete Bioactive Restorative System for Occlusal Restorations Between Diabetic and Non-diabetic Patients.","A Prospective Clinical Evaluation of Bioactive Restorative System in Controlled Diabetic and Non Diabetic Patients: An 18-Month Non-Randomized Comparative Study.","Inclusion Criteria:\n\n* Patients indicated for a Class I posterior composite restoration\n* permanent tooth\n* ICDAS 3 or 4\n\nExclusion Criteria:\n\n* uncontrolled diabetic patients\n* primary dentition\n* special needs",true,"20 Years",{"count":56,"type":20},50,[23],"This study is conducted to evaluate the 18-month clinical performance of complete bioactive restorative system for occlusal restorations between diabetic and non-diabetic patients.",[27],[61],"Bioactive composite","2026-02-24",{"date":64,"type":39},"2026-02-25",{"date":66,"type":20},"2026-08-01",{"date":68,"type":20},"2028-04-01",{"name":70,"class":45},"Cairo University",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":53,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":81,"phases":4,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100617261","central-sensitization-in-painful-and-painless-diabetic-peripheral-neuropathy-100617261","NCT07316322","Central Sensitization in Painful and Painless Diabetic Peripheral Neuropathy","Comparison of Central Sensitization in Painful and Painless Diabetic Peripheral Neuropathy Phenotypes: A Multidimensional Psychophysiological Assessment","Inclusion Criteria:\n\n* Being between 18 and 80 years of age\n* Having a diagnosis of Type 2 diabetes mellitus for at least 1 year\n* Providing written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Non-diabetic causes of polyneuropathy (alcohol, chemotherapy, vitamin deficiencies, renal failure, hypothyroidism, etc.)\n* Active ulcer, infection, or severe vascular insufficiency in the lower extremity\n* Central nervous system disorders (stroke, multiple sclerosis, spinal cord injury, etc.)\n* Skin lesions, dermatitis, wounds, or infection in the test areas (foot or forearm)\n* Peripheral entrapment neuropathies or related radiculopathies (e.g., carpal tunnel syndrome, C7-C8 radiculopathy)\n* Chronic widespread pain syndrome (fibromyalgia, etc.) or active flaring rheumatologic disease\n* Dose change within the last 2-4 weeks in medications affecting pain modulation (gabapentinoids, SNRI\u002FTCA, opioids, hypnotics, etc.)","80 Years",{"count":80,"type":20},128,"OBSERVATIONAL","This research is structured as a cross-sectional observational study. The primary objective is to compare central sensitization across painful and painless phenotypes of diabetic peripheral neuropathy. The study will be conducted among individuals diagnosed with type 2 diabetes mellitus at the Department of Geriatrics, İnönü University Turgut Özal Medical Center. All assessments will be administered in accordance with a rigorously standardized protocol.\n\nEligible participants will include individuals aged 18 to 80 years who have had a confirmed diagnosis of type 2 diabetes mellitus for at least one year, are capable of comprehending and following verbal instructions in Turkish required for the study procedures, and provide written informed consent.\n\nAll statistical analyses will be performed using IBM SPSS Statistics (v.29, Armonk, NY, USA) and JASP (v.0.18, Amsterdam, Netherlands).",[27],[85,86,87,88],"Diabetus Mellitus","Central sensitization","Temporal summation","Neuropathic pain","2026-01-01",{"date":91,"type":39},"2026-01-05",{"date":93,"type":20},"2025-12-15",{"date":95,"type":20},"2026-09-15",{"name":97,"class":45},"Inonu University",1]